Q2 EPS Estimates for Traws Pharma Lifted by HC Wainwright

Traws Pharma, Inc. (NASDAQ:TRAW) – Equities research analysts at HC Wainwright lifted their Q2 2026 EPS estimates for shares of Traws Pharma in a research note issued on Wednesday, May 20th. HC Wainwright analyst B. Folkes now anticipates that the company will earn ($0.41) per share for the quarter, up from their previous forecast of ($0.54). HC Wainwright has a “Buy” rating and a $8.00 price target on the stock. The consensus estimate for Traws Pharma’s current full-year earnings is ($2.72) per share. HC Wainwright also issued estimates for Traws Pharma’s Q3 2026 earnings at ($0.20) EPS, Q4 2026 earnings at ($0.23) EPS, FY2026 earnings at ($1.31) EPS, FY2027 earnings at ($0.55) EPS, FY2028 earnings at ($0.11) EPS and FY2029 earnings at $0.24 EPS.

Traws Pharma (NASDAQ:TRAW) last posted its quarterly earnings results on Friday, May 15th. The company reported ($0.53) EPS for the quarter, topping the consensus estimate of ($0.92) by $0.39.

Other equities research analysts have also issued research reports about the company. LADENBURG THALM/SH SH raised Traws Pharma to a “strong-buy” rating in a research report on Friday, January 30th. Weiss Ratings downgraded Traws Pharma from a “sell (d+)” rating to a “sell (d)” rating in a research report on Friday, May 15th. One equities research analyst has rated the stock with a Strong Buy rating, one has given a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Traws Pharma currently has an average rating of “Moderate Buy” and a consensus target price of $8.00.

Traws Pharma Trading Down 8.0%

NASDAQ:TRAW opened at $1.49 on Friday. Traws Pharma has a 12-month low of $1.00 and a 12-month high of $3.27. The firm has a market cap of $15.14 million, a PE ratio of -0.88 and a beta of 1.47. The stock has a fifty day moving average price of $1.68 and a 200 day moving average price of $1.82.

Insider Transactions at Traws Pharma

In related news, major shareholder Orbimed Advisors Llc purchased 597,729 shares of the company’s stock in a transaction on Thursday, April 16th. The shares were bought at an average cost of $1.67 per share, for a total transaction of $998,207.43. Following the completion of the purchase, the insider directly owned 1,203,250 shares of the company’s stock, valued at approximately $2,009,427.50. This trade represents a 98.71% increase in their position. The purchase was disclosed in a legal filing with the SEC, which can be accessed through this link. 14.00% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of the stock. Two Sigma Investments LP lifted its position in Traws Pharma by 37.1% in the third quarter. Two Sigma Investments LP now owns 22,018 shares of the company’s stock valued at $41,000 after acquiring an additional 5,955 shares during the last quarter. Geode Capital Management LLC increased its holdings in shares of Traws Pharma by 41.9% in the 4th quarter. Geode Capital Management LLC now owns 61,653 shares of the company’s stock valued at $70,000 after acquiring an additional 18,213 shares during the period. State Street Corp purchased a new stake in Traws Pharma in the 4th quarter valued at $29,000. XTX Topco Ltd boosted its stake in Traws Pharma by 294.2% during the 4th quarter. XTX Topco Ltd now owns 42,210 shares of the company’s stock worth $48,000 after purchasing an additional 31,502 shares during the period. Finally, Seven Fleet Capital Management LP acquired a new stake in Traws Pharma during the 4th quarter worth $56,000. Institutional investors and hedge funds own 7.95% of the company’s stock.

About Traws Pharma

Traws Pharma, Inc, a clinical stage biopharmaceutical company, focuses on developing small molecule oral product candidates for respiratory viral diseases and cancer. The company is developing investigational novel therapies for influenza and COVID19 that are designed to address treatment resistance, such as TRX01 (travatrelvir), a Mpro/3CL inhibitor in development for the treatment of COVID19; and TRX100 (viroxavir), an endonuclease inhibitor in development for the treatment of pandemic influenza.